![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves Jazz’s Vyxeos for AML Variants
FDA Approves Jazz’s Vyxeos for AML Variants
![ApprovedGreen.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/ApprovedGreen.gif?t=1576044289&width=430)
The FDA approved Vyxeos, the brand name for Jazz Pharamaceuticals’ combination of the chemotherapy drugs daunorubicin and cytarabine, for the treatment of adults with two types of poor-prognosis acute myeloid leukemia: newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vyxeos may help some patients live longer than if they were to receive the two therapies separately, the agency said.
T-AML occurs as a complication of chemotherapy or radiation in approximately 8 to10 percent of all patients receiving those treatments for cancer. AML-MRC is characterized by a history of certain blood disorders and mutations within cancer cells.
Upcoming Events
-
21Oct